€ million |
|
Note |
|
2024 |
|
2023 |
||||
|---|---|---|---|---|---|---|---|---|---|---|
Net sales |
|
|
21,156 |
|
20,993 |
|||||
Cost of sales |
|
|
-8,671 |
|
-8,600 |
|||||
Gross profit |
|
|
|
12,485 |
|
12,392 |
||||
|
|
|
|
|
|
|
||||
Marketing and selling expenses |
|
|
-4,536 |
|
-4,510 |
|||||
Administration expenses |
|
|
|
-1,370 |
|
-1,392 |
||||
Research and development costs |
|
|
-2,279 |
|
-2,445 |
|||||
Impairment losses and reversals of impairment losses on financial assets (net) |
|
|
-8 |
|
-51 |
|||||
Other operating income |
|
|
269 |
|
445 |
|||||
Other operating expenses |
|
|
-915 |
|
-830 |
|||||
Operating result (EBIT)1 |
|
|
|
3,645 |
|
3,609 |
||||
|
|
|
|
|
|
|
||||
Finance income |
|
|
200 |
|
197 |
|||||
Finance costs |
|
|
-309 |
|
-322 |
|||||
Profit before income tax |
|
|
|
3,536 |
|
3,484 |
||||
|
|
|
|
|
|
|
||||
Income tax |
|
|
-751 |
|
-650 |
|||||
Profit after tax |
|
|
|
2,786 |
|
2,834 |
||||
thereof: attributable to shareholders of Merck KGaA, Darmstadt, Germany (net income) |
|
|
|
2,777 |
|
2,824 |
||||
thereof: attributable to non-controlling interests |
|
|
9 |
|
10 |
|||||
|
|
|
|
|
|
|
||||
Earnings per share (in €) |
|
|
|
|
|
|||||
Basic |
|
|
|
6.39 |
|
6.49 |
||||
Diluted |
|
|
|
6.39 |
|
6.49 |
||||
|
||||||||||